INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47801, 17752, 'Docetaxel', 'Bone Marrow Failure Disorders', 'The use of docetaxel is contraindicated in patients with a neutrophil count < 1500/mm3.  Docetaxel induces dose-related myelosuppression resulting in neutropenia, thrombocytopenia, and anemia.  Neutropenia occurs in all patients administered 60-100 mg/m2 of docetaxel.  Grade 4 neutropenia (< 500/mm3) occurs in nearly all patients administered 100 mg/m2 of docetaxel.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, or local infection.  Therapy should be administered cautiously to patients with compromised bone marrow reserve and should be withheld until neutrophil levels is > 1500/mm3 and/or platelet counts is > 100,000/mm3.  A 25% reduction in dosage is recommended during subsequent cycles following severe neutropenia (< 500/mm3).  It is recommended to performed frequent blood cell counts on all patients receiving docetaxel.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47802, 18656, 'Docetaxel', 'Bone Marrow Failure Disorders', 'The use of docetaxel is contraindicated in patients with a neutrophil count < 1500/mm3.  Docetaxel induces dose-related myelosuppression resulting in neutropenia, thrombocytopenia, and anemia.  Neutropenia occurs in all patients administered 60-100 mg/m2 of docetaxel.  Grade 4 neutropenia (< 500/mm3) occurs in nearly all patients administered 100 mg/m2 of docetaxel.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, or local infection.  Therapy should be administered cautiously to patients with compromised bone marrow reserve and should be withheld until neutrophil levels is > 1500/mm3 and/or platelet counts is > 100,000/mm3.  A 25% reduction in dosage is recommended during subsequent cycles following severe neutropenia (< 500/mm3).  It is recommended to performed frequent blood cell counts on all patients receiving docetaxel.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47803, 18657, 'Docetaxel', 'Bone Marrow Failure Disorders', 'The use of docetaxel is contraindicated in patients with a neutrophil count < 1500/mm3.  Docetaxel induces dose-related myelosuppression resulting in neutropenia, thrombocytopenia, and anemia.  Neutropenia occurs in all patients administered 60-100 mg/m2 of docetaxel.  Grade 4 neutropenia (< 500/mm3) occurs in nearly all patients administered 100 mg/m2 of docetaxel.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, or local infection.  Therapy should be administered cautiously to patients with compromised bone marrow reserve and should be withheld until neutrophil levels is > 1500/mm3 and/or platelet counts is > 100,000/mm3.  A 25% reduction in dosage is recommended during subsequent cycles following severe neutropenia (< 500/mm3).  It is recommended to performed frequent blood cell counts on all patients receiving docetaxel.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47804, 32756, 'Docetaxel', 'Bone Marrow Failure Disorders', 'The use of docetaxel is contraindicated in patients with a neutrophil count < 1500/mm3.  Docetaxel induces dose-related myelosuppression resulting in neutropenia, thrombocytopenia, and anemia.  Neutropenia occurs in all patients administered 60-100 mg/m2 of docetaxel.  Grade 4 neutropenia (< 500/mm3) occurs in nearly all patients administered 100 mg/m2 of docetaxel.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, or local infection.  Therapy should be administered cautiously to patients with compromised bone marrow reserve and should be withheld until neutrophil levels is > 1500/mm3 and/or platelet counts is > 100,000/mm3.  A 25% reduction in dosage is recommended during subsequent cycles following severe neutropenia (< 500/mm3).  It is recommended to performed frequent blood cell counts on all patients receiving docetaxel.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47805, 32757, 'Docetaxel', 'Bone Marrow Failure Disorders', 'The use of docetaxel is contraindicated in patients with a neutrophil count < 1500/mm3.  Docetaxel induces dose-related myelosuppression resulting in neutropenia, thrombocytopenia, and anemia.  Neutropenia occurs in all patients administered 60-100 mg/m2 of docetaxel.  Grade 4 neutropenia (< 500/mm3) occurs in nearly all patients administered 100 mg/m2 of docetaxel.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, or local infection.  Therapy should be administered cautiously to patients with compromised bone marrow reserve and should be withheld until neutrophil levels is > 1500/mm3 and/or platelet counts is > 100,000/mm3.  A 25% reduction in dosage is recommended during subsequent cycles following severe neutropenia (< 500/mm3).  It is recommended to performed frequent blood cell counts on all patients receiving docetaxel.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47806, 11214, 'Docetaxel', 'Alcoholism', 'The alcohol content in a dose of docetaxel injection may affect the central nervous system.  Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content.  Close monitoring is recommended in alcoholic patients.  Consideration should be given to the alcohol content in docetaxel injection on the ability to drive or use machines immediately after the infusion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47807, 11215, 'Docetaxel', 'Alcoholism', 'The alcohol content in a dose of docetaxel injection may affect the central nervous system.  Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content.  Close monitoring is recommended in alcoholic patients.  Consideration should be given to the alcohol content in docetaxel injection on the ability to drive or use machines immediately after the infusion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47808, 17133, 'Docetaxel', 'Alcoholism', 'The alcohol content in a dose of docetaxel injection may affect the central nervous system.  Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content.  Close monitoring is recommended in alcoholic patients.  Consideration should be given to the alcohol content in docetaxel injection on the ability to drive or use machines immediately after the infusion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47809, 17134, 'Docetaxel', 'Alcoholism', 'The alcohol content in a dose of docetaxel injection may affect the central nervous system.  Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content.  Close monitoring is recommended in alcoholic patients.  Consideration should be given to the alcohol content in docetaxel injection on the ability to drive or use machines immediately after the infusion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47810, 17748, 'Docetaxel', 'Alcoholism', 'The alcohol content in a dose of docetaxel injection may affect the central nervous system.  Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content.  Close monitoring is recommended in alcoholic patients.  Consideration should be given to the alcohol content in docetaxel injection on the ability to drive or use machines immediately after the infusion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47811, 17749, 'Docetaxel', 'Alcoholism', 'The alcohol content in a dose of docetaxel injection may affect the central nervous system.  Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content.  Close monitoring is recommended in alcoholic patients.  Consideration should be given to the alcohol content in docetaxel injection on the ability to drive or use machines immediately after the infusion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47812, 17750, 'Docetaxel', 'Alcoholism', 'The alcohol content in a dose of docetaxel injection may affect the central nervous system.  Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content.  Close monitoring is recommended in alcoholic patients.  Consideration should be given to the alcohol content in docetaxel injection on the ability to drive or use machines immediately after the infusion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47813, 17751, 'Docetaxel', 'Alcoholism', 'The alcohol content in a dose of docetaxel injection may affect the central nervous system.  Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content.  Close monitoring is recommended in alcoholic patients.  Consideration should be given to the alcohol content in docetaxel injection on the ability to drive or use machines immediately after the infusion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47814, 17752, 'Docetaxel', 'Alcoholism', 'The alcohol content in a dose of docetaxel injection may affect the central nervous system.  Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content.  Close monitoring is recommended in alcoholic patients.  Consideration should be given to the alcohol content in docetaxel injection on the ability to drive or use machines immediately after the infusion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47815, 18656, 'Docetaxel', 'Alcoholism', 'The alcohol content in a dose of docetaxel injection may affect the central nervous system.  Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content.  Close monitoring is recommended in alcoholic patients.  Consideration should be given to the alcohol content in docetaxel injection on the ability to drive or use machines immediately after the infusion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47816, 18657, 'Docetaxel', 'Alcoholism', 'The alcohol content in a dose of docetaxel injection may affect the central nervous system.  Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content.  Close monitoring is recommended in alcoholic patients.  Consideration should be given to the alcohol content in docetaxel injection on the ability to drive or use machines immediately after the infusion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47817, 32756, 'Docetaxel', 'Alcoholism', 'The alcohol content in a dose of docetaxel injection may affect the central nervous system.  Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content.  Close monitoring is recommended in alcoholic patients.  Consideration should be given to the alcohol content in docetaxel injection on the ability to drive or use machines immediately after the infusion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47818, 32757, 'Docetaxel', 'Alcoholism', 'The alcohol content in a dose of docetaxel injection may affect the central nervous system.  Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content.  Close monitoring is recommended in alcoholic patients.  Consideration should be given to the alcohol content in docetaxel injection on the ability to drive or use machines immediately after the infusion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47819, 11214, 'Docetaxel', 'Paresthesia', 'Severe neurosensory symptoms such as paresthesia, dysesthesia, and pain have been reported during docetaxel therapy.  Therapy with docetaxel should be administered cautiously to patients with or predisposition to neurosensory symptoms.  Although reversible with discontinuation of docetaxel therapy, the dosage must be adjusted if neurosensory symptoms occur and therapy discontinued if symptoms persist.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47820, 11215, 'Docetaxel', 'Paresthesia', 'Severe neurosensory symptoms such as paresthesia, dysesthesia, and pain have been reported during docetaxel therapy.  Therapy with docetaxel should be administered cautiously to patients with or predisposition to neurosensory symptoms.  Although reversible with discontinuation of docetaxel therapy, the dosage must be adjusted if neurosensory symptoms occur and therapy discontinued if symptoms persist.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47821, 17133, 'Docetaxel', 'Paresthesia', 'Severe neurosensory symptoms such as paresthesia, dysesthesia, and pain have been reported during docetaxel therapy.  Therapy with docetaxel should be administered cautiously to patients with or predisposition to neurosensory symptoms.  Although reversible with discontinuation of docetaxel therapy, the dosage must be adjusted if neurosensory symptoms occur and therapy discontinued if symptoms persist.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47822, 17134, 'Docetaxel', 'Paresthesia', 'Severe neurosensory symptoms such as paresthesia, dysesthesia, and pain have been reported during docetaxel therapy.  Therapy with docetaxel should be administered cautiously to patients with or predisposition to neurosensory symptoms.  Although reversible with discontinuation of docetaxel therapy, the dosage must be adjusted if neurosensory symptoms occur and therapy discontinued if symptoms persist.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47823, 17748, 'Docetaxel', 'Paresthesia', 'Severe neurosensory symptoms such as paresthesia, dysesthesia, and pain have been reported during docetaxel therapy.  Therapy with docetaxel should be administered cautiously to patients with or predisposition to neurosensory symptoms.  Although reversible with discontinuation of docetaxel therapy, the dosage must be adjusted if neurosensory symptoms occur and therapy discontinued if symptoms persist.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47824, 17749, 'Docetaxel', 'Paresthesia', 'Severe neurosensory symptoms such as paresthesia, dysesthesia, and pain have been reported during docetaxel therapy.  Therapy with docetaxel should be administered cautiously to patients with or predisposition to neurosensory symptoms.  Although reversible with discontinuation of docetaxel therapy, the dosage must be adjusted if neurosensory symptoms occur and therapy discontinued if symptoms persist.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47825, 17750, 'Docetaxel', 'Paresthesia', 'Severe neurosensory symptoms such as paresthesia, dysesthesia, and pain have been reported during docetaxel therapy.  Therapy with docetaxel should be administered cautiously to patients with or predisposition to neurosensory symptoms.  Although reversible with discontinuation of docetaxel therapy, the dosage must be adjusted if neurosensory symptoms occur and therapy discontinued if symptoms persist.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47826, 17751, 'Docetaxel', 'Paresthesia', 'Severe neurosensory symptoms such as paresthesia, dysesthesia, and pain have been reported during docetaxel therapy.  Therapy with docetaxel should be administered cautiously to patients with or predisposition to neurosensory symptoms.  Although reversible with discontinuation of docetaxel therapy, the dosage must be adjusted if neurosensory symptoms occur and therapy discontinued if symptoms persist.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47827, 17752, 'Docetaxel', 'Paresthesia', 'Severe neurosensory symptoms such as paresthesia, dysesthesia, and pain have been reported during docetaxel therapy.  Therapy with docetaxel should be administered cautiously to patients with or predisposition to neurosensory symptoms.  Although reversible with discontinuation of docetaxel therapy, the dosage must be adjusted if neurosensory symptoms occur and therapy discontinued if symptoms persist.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47828, 18656, 'Docetaxel', 'Paresthesia', 'Severe neurosensory symptoms such as paresthesia, dysesthesia, and pain have been reported during docetaxel therapy.  Therapy with docetaxel should be administered cautiously to patients with or predisposition to neurosensory symptoms.  Although reversible with discontinuation of docetaxel therapy, the dosage must be adjusted if neurosensory symptoms occur and therapy discontinued if symptoms persist.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47829, 18657, 'Docetaxel', 'Paresthesia', 'Severe neurosensory symptoms such as paresthesia, dysesthesia, and pain have been reported during docetaxel therapy.  Therapy with docetaxel should be administered cautiously to patients with or predisposition to neurosensory symptoms.  Although reversible with discontinuation of docetaxel therapy, the dosage must be adjusted if neurosensory symptoms occur and therapy discontinued if symptoms persist.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47830, 32756, 'Docetaxel', 'Paresthesia', 'Severe neurosensory symptoms such as paresthesia, dysesthesia, and pain have been reported during docetaxel therapy.  Therapy with docetaxel should be administered cautiously to patients with or predisposition to neurosensory symptoms.  Although reversible with discontinuation of docetaxel therapy, the dosage must be adjusted if neurosensory symptoms occur and therapy discontinued if symptoms persist.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47831, 32757, 'Docetaxel', 'Paresthesia', 'Severe neurosensory symptoms such as paresthesia, dysesthesia, and pain have been reported during docetaxel therapy.  Therapy with docetaxel should be administered cautiously to patients with or predisposition to neurosensory symptoms.  Although reversible with discontinuation of docetaxel therapy, the dosage must be adjusted if neurosensory symptoms occur and therapy discontinued if symptoms persist.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47832, 21657, 'Aluminum hydroxide', 'Constipation', 'Aluminum containing antacids may produce constipation, which may lead to intestinal obstruction.  Osteomalacia and hypophosphatemia may be produced in patients with renal dysfunction who are not receiving dialysis.  Patients with renal dysfunction, intestinal obstruction, osteomalacia, or hypophosphatemia should use antacids with low or no aluminum content.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47833, 0, 'Doxapram', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47834, 0, 'Doxapram', 'Craniocerebral Trauma', 'The use of doxapram is contraindicated in patients with head injury, cerebral vascular accident, or cerebral edema.  Existing coma may worsen with doxapram administration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47835, 0, 'Doxapram', 'Lung Diseases', 'The use of doxapram is contraindicated in patients with mechanical disorders of ventilation such as mechanical obstruction, muscle paresis, flail chest, pneumothorax, acute bronchial asthma, pulmonary fibrosis or other conditions resulting in restriction of chest wall, muscles of respiration or alveolar expansion.  Doxapram is not effective in stimulating respiration in these patients.  Doxapram should not be used in patients under mechanical ventilation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47836, 0, 'Doxapram', 'Epilepsy', 'The use of doxapram is contraindicated in patients with seizure disorders.  In high doses, doxapram may produce tonic-clonic seizures by CNS stimulation effects.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47837, 0, 'Doxapram', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47838, 0, 'Doxapram', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47839, 0, 'Doxapram', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47840, 0, 'Alvimopan', 'Intestinal Obstruction', 'Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.  Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn''s disease, infiltrative GI tract malignancies or peritoneal metastases.  It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms.  The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47841, 0, 'Dofetilide', 'Long QT Syndrome', 'Dofetilide is contraindicated in patients with congenital or acquired long QT syndromes.  Dofetilide should not be used in patients with a baseline QT interval of QTc >440 msec (500 msec in patients with ventricular conduction abnormalities).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47842, 0, 'Dofetilide', 'Kidney Diseases', 'Dofetilide is contraindicated in patients with severe renal impairment (calculated creatinine clearance <20 mL/min).  The risk of QT interval prolongation, Torsade de Pointes, and ventricular arrhythmias is directly related to dofetilide plasma concentration.  A reduced creatinine clearance will increase dofetilide plasma concentration.  In patients with mild and moderate renal impairment, the risk of arrhythmias can be reduced by controlling the plasma concentration through adjustment of the initial dofetilide dose according to creatinine clearance.  Patients undergoing dialysis were not included in clinical studies, and appropriate dosing recommendations for these patients are unknown.  There is no information about the effectiveness of hemodialysis in removing dofetilide from plasma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47843, 0, 'Dofetilide', 'Water-Electrolyte Imbalance', 'Dofetilide should be avoided in patients that experience symptoms that may be associated with altered electrolyte balance, such as excessive or prolonged diarrhea, sweating, or vomiting or loss of appetite or thirst, these conditions should immediately be reported to their health care provider.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47844, 0, 'Dofetilide', 'Hepatic Insufficiency', 'Dofetilide has not been studied in patients with severe hepatic impairment.  Dofetilide should be used with particular caution in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47845, 0, 'Dofetilide', 'Hypokalemia', 'Serum potassium should be maintained within the normal range before dofetilide treatment is initiated and should be maintained within the normal range while the patient remains on dofetilide therapy.  In clinical trials, potassium levels were generally maintained above 3.6 to 4.0 mEq/L.  Exercise care when using this agent in patients with hypokalemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47846, 6907, 'Doxorubicin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47847, 6911, 'Doxorubicin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47848, 13510, 'Doxorubicin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47849, 13511, 'Doxorubicin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47850, 17879, 'Doxorubicin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47851, 17880, 'Doxorubicin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47852, 17881, 'Doxorubicin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47853, 17882, 'Doxorubicin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47854, 17883, 'Doxorubicin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47855, 17885, 'Doxorubicin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47856, 24108, 'Doxorubicin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47857, 24109, 'Doxorubicin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47858, 6907, 'Doxorubicin', 'Cardiomyopathies', 'Myocardial damage, including acute left ventricular failure can occur with doxorubicin.  The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20% for cumulative doses ranging from 300 mg/m2 to 500 mg/m2 when doxorubicin is administered every 3 weeks.  The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy.  Additionally, doxorubicin can also cause arrhythmias, including life-threatening events at any point during treatment.  Assess LVEF before and regularly during and after treatment with doxorubicin.  Doxorubicin is contraindicated in patients with severe myocardial insufficiency and recent myocardial infarction (past 6 months).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47859, 6911, 'Doxorubicin', 'Cardiomyopathies', 'Myocardial damage, including acute left ventricular failure can occur with doxorubicin.  The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20% for cumulative doses ranging from 300 mg/m2 to 500 mg/m2 when doxorubicin is administered every 3 weeks.  The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy.  Additionally, doxorubicin can also cause arrhythmias, including life-threatening events at any point during treatment.  Assess LVEF before and regularly during and after treatment with doxorubicin.  Doxorubicin is contraindicated in patients with severe myocardial insufficiency and recent myocardial infarction (past 6 months).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47860, 13510, 'Doxorubicin', 'Cardiomyopathies', 'Myocardial damage, including acute left ventricular failure can occur with doxorubicin.  The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20% for cumulative doses ranging from 300 mg/m2 to 500 mg/m2 when doxorubicin is administered every 3 weeks.  The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy.  Additionally, doxorubicin can also cause arrhythmias, including life-threatening events at any point during treatment.  Assess LVEF before and regularly during and after treatment with doxorubicin.  Doxorubicin is contraindicated in patients with severe myocardial insufficiency and recent myocardial infarction (past 6 months).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47861, 13511, 'Doxorubicin', 'Cardiomyopathies', 'Myocardial damage, including acute left ventricular failure can occur with doxorubicin.  The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20% for cumulative doses ranging from 300 mg/m2 to 500 mg/m2 when doxorubicin is administered every 3 weeks.  The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy.  Additionally, doxorubicin can also cause arrhythmias, including life-threatening events at any point during treatment.  Assess LVEF before and regularly during and after treatment with doxorubicin.  Doxorubicin is contraindicated in patients with severe myocardial insufficiency and recent myocardial infarction (past 6 months).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47862, 17879, 'Doxorubicin', 'Cardiomyopathies', 'Myocardial damage, including acute left ventricular failure can occur with doxorubicin.  The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20% for cumulative doses ranging from 300 mg/m2 to 500 mg/m2 when doxorubicin is administered every 3 weeks.  The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy.  Additionally, doxorubicin can also cause arrhythmias, including life-threatening events at any point during treatment.  Assess LVEF before and regularly during and after treatment with doxorubicin.  Doxorubicin is contraindicated in patients with severe myocardial insufficiency and recent myocardial infarction (past 6 months).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47863, 17880, 'Doxorubicin', 'Cardiomyopathies', 'Myocardial damage, including acute left ventricular failure can occur with doxorubicin.  The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20% for cumulative doses ranging from 300 mg/m2 to 500 mg/m2 when doxorubicin is administered every 3 weeks.  The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy.  Additionally, doxorubicin can also cause arrhythmias, including life-threatening events at any point during treatment.  Assess LVEF before and regularly during and after treatment with doxorubicin.  Doxorubicin is contraindicated in patients with severe myocardial insufficiency and recent myocardial infarction (past 6 months).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47864, 17881, 'Doxorubicin', 'Cardiomyopathies', 'Myocardial damage, including acute left ventricular failure can occur with doxorubicin.  The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20% for cumulative doses ranging from 300 mg/m2 to 500 mg/m2 when doxorubicin is administered every 3 weeks.  The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy.  Additionally, doxorubicin can also cause arrhythmias, including life-threatening events at any point during treatment.  Assess LVEF before and regularly during and after treatment with doxorubicin.  Doxorubicin is contraindicated in patients with severe myocardial insufficiency and recent myocardial infarction (past 6 months).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47865, 17882, 'Doxorubicin', 'Cardiomyopathies', 'Myocardial damage, including acute left ventricular failure can occur with doxorubicin.  The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20% for cumulative doses ranging from 300 mg/m2 to 500 mg/m2 when doxorubicin is administered every 3 weeks.  The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy.  Additionally, doxorubicin can also cause arrhythmias, including life-threatening events at any point during treatment.  Assess LVEF before and regularly during and after treatment with doxorubicin.  Doxorubicin is contraindicated in patients with severe myocardial insufficiency and recent myocardial infarction (past 6 months).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47866, 17883, 'Doxorubicin', 'Cardiomyopathies', 'Myocardial damage, including acute left ventricular failure can occur with doxorubicin.  The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20% for cumulative doses ranging from 300 mg/m2 to 500 mg/m2 when doxorubicin is administered every 3 weeks.  The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy.  Additionally, doxorubicin can also cause arrhythmias, including life-threatening events at any point during treatment.  Assess LVEF before and regularly during and after treatment with doxorubicin.  Doxorubicin is contraindicated in patients with severe myocardial insufficiency and recent myocardial infarction (past 6 months).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47867, 17885, 'Doxorubicin', 'Cardiomyopathies', 'Myocardial damage, including acute left ventricular failure can occur with doxorubicin.  The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20% for cumulative doses ranging from 300 mg/m2 to 500 mg/m2 when doxorubicin is administered every 3 weeks.  The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy.  Additionally, doxorubicin can also cause arrhythmias, including life-threatening events at any point during treatment.  Assess LVEF before and regularly during and after treatment with doxorubicin.  Doxorubicin is contraindicated in patients with severe myocardial insufficiency and recent myocardial infarction (past 6 months).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47868, 24108, 'Doxorubicin', 'Cardiomyopathies', 'Myocardial damage, including acute left ventricular failure can occur with doxorubicin.  The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20% for cumulative doses ranging from 300 mg/m2 to 500 mg/m2 when doxorubicin is administered every 3 weeks.  The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy.  Additionally, doxorubicin can also cause arrhythmias, including life-threatening events at any point during treatment.  Assess LVEF before and regularly during and after treatment with doxorubicin.  Doxorubicin is contraindicated in patients with severe myocardial insufficiency and recent myocardial infarction (past 6 months).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47869, 24109, 'Doxorubicin', 'Cardiomyopathies', 'Myocardial damage, including acute left ventricular failure can occur with doxorubicin.  The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20% for cumulative doses ranging from 300 mg/m2 to 500 mg/m2 when doxorubicin is administered every 3 weeks.  The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy.  Additionally, doxorubicin can also cause arrhythmias, including life-threatening events at any point during treatment.  Assess LVEF before and regularly during and after treatment with doxorubicin.  Doxorubicin is contraindicated in patients with severe myocardial insufficiency and recent myocardial infarction (past 6 months).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47870, 6907, 'Doxorubicin', 'Liver Diseases', 'Doxorubicin is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL).  Doxorubicin is primarily metabolized by the liver and its clearance is reduced in the presence of hepatic dysfunction, increasing the risk for toxicity.  Therapy with doxorubicin should be administered cautiously and at a reduced dosage in patients with moderate or mild hepatic function.  Close clinical monitoring of hepatic function prior to initiation of doxorubicin therapy is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47871, 6911, 'Doxorubicin', 'Liver Diseases', 'Doxorubicin is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL).  Doxorubicin is primarily metabolized by the liver and its clearance is reduced in the presence of hepatic dysfunction, increasing the risk for toxicity.  Therapy with doxorubicin should be administered cautiously and at a reduced dosage in patients with moderate or mild hepatic function.  Close clinical monitoring of hepatic function prior to initiation of doxorubicin therapy is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47872, 13510, 'Doxorubicin', 'Liver Diseases', 'Doxorubicin is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL).  Doxorubicin is primarily metabolized by the liver and its clearance is reduced in the presence of hepatic dysfunction, increasing the risk for toxicity.  Therapy with doxorubicin should be administered cautiously and at a reduced dosage in patients with moderate or mild hepatic function.  Close clinical monitoring of hepatic function prior to initiation of doxorubicin therapy is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47873, 13511, 'Doxorubicin', 'Liver Diseases', 'Doxorubicin is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL).  Doxorubicin is primarily metabolized by the liver and its clearance is reduced in the presence of hepatic dysfunction, increasing the risk for toxicity.  Therapy with doxorubicin should be administered cautiously and at a reduced dosage in patients with moderate or mild hepatic function.  Close clinical monitoring of hepatic function prior to initiation of doxorubicin therapy is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47874, 17879, 'Doxorubicin', 'Liver Diseases', 'Doxorubicin is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL).  Doxorubicin is primarily metabolized by the liver and its clearance is reduced in the presence of hepatic dysfunction, increasing the risk for toxicity.  Therapy with doxorubicin should be administered cautiously and at a reduced dosage in patients with moderate or mild hepatic function.  Close clinical monitoring of hepatic function prior to initiation of doxorubicin therapy is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47875, 17880, 'Doxorubicin', 'Liver Diseases', 'Doxorubicin is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL).  Doxorubicin is primarily metabolized by the liver and its clearance is reduced in the presence of hepatic dysfunction, increasing the risk for toxicity.  Therapy with doxorubicin should be administered cautiously and at a reduced dosage in patients with moderate or mild hepatic function.  Close clinical monitoring of hepatic function prior to initiation of doxorubicin therapy is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47876, 17881, 'Doxorubicin', 'Liver Diseases', 'Doxorubicin is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL).  Doxorubicin is primarily metabolized by the liver and its clearance is reduced in the presence of hepatic dysfunction, increasing the risk for toxicity.  Therapy with doxorubicin should be administered cautiously and at a reduced dosage in patients with moderate or mild hepatic function.  Close clinical monitoring of hepatic function prior to initiation of doxorubicin therapy is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47877, 17882, 'Doxorubicin', 'Liver Diseases', 'Doxorubicin is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL).  Doxorubicin is primarily metabolized by the liver and its clearance is reduced in the presence of hepatic dysfunction, increasing the risk for toxicity.  Therapy with doxorubicin should be administered cautiously and at a reduced dosage in patients with moderate or mild hepatic function.  Close clinical monitoring of hepatic function prior to initiation of doxorubicin therapy is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47878, 17883, 'Doxorubicin', 'Liver Diseases', 'Doxorubicin is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL).  Doxorubicin is primarily metabolized by the liver and its clearance is reduced in the presence of hepatic dysfunction, increasing the risk for toxicity.  Therapy with doxorubicin should be administered cautiously and at a reduced dosage in patients with moderate or mild hepatic function.  Close clinical monitoring of hepatic function prior to initiation of doxorubicin therapy is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47879, 17885, 'Doxorubicin', 'Liver Diseases', 'Doxorubicin is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL).  Doxorubicin is primarily metabolized by the liver and its clearance is reduced in the presence of hepatic dysfunction, increasing the risk for toxicity.  Therapy with doxorubicin should be administered cautiously and at a reduced dosage in patients with moderate or mild hepatic function.  Close clinical monitoring of hepatic function prior to initiation of doxorubicin therapy is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47880, 24108, 'Doxorubicin', 'Liver Diseases', 'Doxorubicin is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL).  Doxorubicin is primarily metabolized by the liver and its clearance is reduced in the presence of hepatic dysfunction, increasing the risk for toxicity.  Therapy with doxorubicin should be administered cautiously and at a reduced dosage in patients with moderate or mild hepatic function.  Close clinical monitoring of hepatic function prior to initiation of doxorubicin therapy is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47881, 24109, 'Doxorubicin', 'Liver Diseases', 'Doxorubicin is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL).  Doxorubicin is primarily metabolized by the liver and its clearance is reduced in the presence of hepatic dysfunction, increasing the risk for toxicity.  Therapy with doxorubicin should be administered cautiously and at a reduced dosage in patients with moderate or mild hepatic function.  Close clinical monitoring of hepatic function prior to initiation of doxorubicin therapy is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47882, 6907, 'Doxorubicin', 'Bone Marrow Failure Disorders', 'Doxorubicin induces dose-related myelosuppression, primarily affecting leukocytes.  Therapy with doxorubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering doxorubicin and the dosage should be reduced.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.  Doxorubicin is contraindicated in patients with severe persistent drug-induced myelosuppression', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47883, 6911, 'Doxorubicin', 'Bone Marrow Failure Disorders', 'Doxorubicin induces dose-related myelosuppression, primarily affecting leukocytes.  Therapy with doxorubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering doxorubicin and the dosage should be reduced.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.  Doxorubicin is contraindicated in patients with severe persistent drug-induced myelosuppression', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47884, 13510, 'Doxorubicin', 'Bone Marrow Failure Disorders', 'Doxorubicin induces dose-related myelosuppression, primarily affecting leukocytes.  Therapy with doxorubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering doxorubicin and the dosage should be reduced.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.  Doxorubicin is contraindicated in patients with severe persistent drug-induced myelosuppression', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47885, 13511, 'Doxorubicin', 'Bone Marrow Failure Disorders', 'Doxorubicin induces dose-related myelosuppression, primarily affecting leukocytes.  Therapy with doxorubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering doxorubicin and the dosage should be reduced.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.  Doxorubicin is contraindicated in patients with severe persistent drug-induced myelosuppression', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47886, 17879, 'Doxorubicin', 'Bone Marrow Failure Disorders', 'Doxorubicin induces dose-related myelosuppression, primarily affecting leukocytes.  Therapy with doxorubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering doxorubicin and the dosage should be reduced.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.  Doxorubicin is contraindicated in patients with severe persistent drug-induced myelosuppression', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47887, 17880, 'Doxorubicin', 'Bone Marrow Failure Disorders', 'Doxorubicin induces dose-related myelosuppression, primarily affecting leukocytes.  Therapy with doxorubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering doxorubicin and the dosage should be reduced.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.  Doxorubicin is contraindicated in patients with severe persistent drug-induced myelosuppression', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47888, 17881, 'Doxorubicin', 'Bone Marrow Failure Disorders', 'Doxorubicin induces dose-related myelosuppression, primarily affecting leukocytes.  Therapy with doxorubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering doxorubicin and the dosage should be reduced.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.  Doxorubicin is contraindicated in patients with severe persistent drug-induced myelosuppression', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47889, 17882, 'Doxorubicin', 'Bone Marrow Failure Disorders', 'Doxorubicin induces dose-related myelosuppression, primarily affecting leukocytes.  Therapy with doxorubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering doxorubicin and the dosage should be reduced.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.  Doxorubicin is contraindicated in patients with severe persistent drug-induced myelosuppression', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47890, 17883, 'Doxorubicin', 'Bone Marrow Failure Disorders', 'Doxorubicin induces dose-related myelosuppression, primarily affecting leukocytes.  Therapy with doxorubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering doxorubicin and the dosage should be reduced.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.  Doxorubicin is contraindicated in patients with severe persistent drug-induced myelosuppression', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47891, 17885, 'Doxorubicin', 'Bone Marrow Failure Disorders', 'Doxorubicin induces dose-related myelosuppression, primarily affecting leukocytes.  Therapy with doxorubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering doxorubicin and the dosage should be reduced.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.  Doxorubicin is contraindicated in patients with severe persistent drug-induced myelosuppression', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47892, 24108, 'Doxorubicin', 'Bone Marrow Failure Disorders', 'Doxorubicin induces dose-related myelosuppression, primarily affecting leukocytes.  Therapy with doxorubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering doxorubicin and the dosage should be reduced.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.  Doxorubicin is contraindicated in patients with severe persistent drug-induced myelosuppression', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47893, 24109, 'Doxorubicin', 'Bone Marrow Failure Disorders', 'Doxorubicin induces dose-related myelosuppression, primarily affecting leukocytes.  Therapy with doxorubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering doxorubicin and the dosage should be reduced.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.  Doxorubicin is contraindicated in patients with severe persistent drug-induced myelosuppression', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47894, 472, 'Donepezil', 'Bradycardia', 'Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities.  Syncopal episodes have been reported in patients with and without cardiac abnormalities.  Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47895, 935, 'Donepezil', 'Bradycardia', 'Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities.  Syncopal episodes have been reported in patients with and without cardiac abnormalities.  Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47896, 936, 'Donepezil', 'Bradycardia', 'Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities.  Syncopal episodes have been reported in patients with and without cardiac abnormalities.  Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47897, 937, 'Donepezil', 'Bradycardia', 'Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities.  Syncopal episodes have been reported in patients with and without cardiac abnormalities.  Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47898, 938, 'Donepezil', 'Bradycardia', 'Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities.  Syncopal episodes have been reported in patients with and without cardiac abnormalities.  Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47899, 1231, 'Donepezil', 'Bradycardia', 'Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities.  Syncopal episodes have been reported in patients with and without cardiac abnormalities.  Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47900, 1331, 'Donepezil', 'Bradycardia', 'Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities.  Syncopal episodes have been reported in patients with and without cardiac abnormalities.  Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.', '3', '', 'DDInter', 0);
